SynthesisMedicine2018
Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in non-muscle invasive bladder cancer: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Prognostic Potential of the Preoperative Controlling Nutritional Status (CONUT) Score in Predicting Survival of Patients with Cancer: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Prognostic Role of Platelet-to-Lymphocyte Ratio in Patients With Bladder Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Association between platelet-to-lymphocyte ratio and high risk for prostate cancer among middle-aged and older US men.Scientific reports · 2026Article
- Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.Cureus · 2025Review
- The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer.Journal of clinical medicine · 2025Article
- The immune landscape of systemic inflammation in prostate cancer.Cancer biology & medicine · 2025Review
- Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance.Journal of clinical laboratory analysis · 2025Article
- Article
- Inflammatory-based prognostic indicators in prostate cancer: evaluating NLR, PLR, and SII in relation to Cambridge and ISUP classifications.Frontiers in oncology · 2025Article
- Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases.World journal of hepatology · 2024Article
- Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review.Asian journal of urology · 2024Review
- Association between platelet‑to‑lymphocyte ratio and serum prostate specific antigen.Molecular and clinical oncology · 2024Article
- Prognostic analysis of stereotactic radiosurgery for brain metastases: a single-center retrospective study.La Radiologia medica · 2023Article
- Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.World journal of urology · 2023Article
- Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review.Translational andrology and urology · 2023Review
- Platelet-to-lymphocyte ratio and the first occurrence of peritonitis in peritoneal dialysis patients.BMC nephrology · 2022Article
- Role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer.Oncology letters · 2022Article
- Prognostic Scoring System Development for Malignant Spinal Cord Compression.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.Pathology oncology research : POR · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, the prognostic value of the platelet-to-lymphocyte ratio (PLR) has been identified in multiple cancers. However, the prognostic significance of the PLR in prostate cancer (PCa) remains conflicting. We therefore searched relevant studies and conducted a meta-analysis.
methodsPapers from the databases of PubMed, Web of Science, and the Cochrane Library were retrieved. Six studies comprising 1324 patients were included.
resultsThe pooled analysis demonstrated that an elevated PLR predicted poor overall survival (OS; HR = 1.85, 95% CI = 1.51-2.25, P < .001) and disease-free survival (DFS; HR = 1.4, 95% CI = 1.1-1.79, P = .007). Subgroup analyses showed that the PLR remained a significant prognostic factor for OS irrespective of ethnicity, tumor stage, or cut-off value. The PLR was an indicator of poor DFS in Asian patients, but not in Caucasian patients. No significant publication bias was detected.
conclusionThis meta-analysis showed that a high PLR was correlated with poor DFS and OS in patients with prostate cancer. Due to this meta-analysis being derived from a few studies, the results should be validated in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.